SCHEMBL5872824

SCHEMBL5872824

Cc1cc(I)ccc1Nc1c(C(=O)O)cc(C(=O)N2CCC(N3CCCC3)CC2)c(F)c1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 10/20 0.48
L3MBTL1 Q9Y468 10/20 0.48
MAP2K2 P36507 5/20 0.47
MAP2K1 Q02750 5/20 0.47
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
TDP1 Q9NUW8 2/20 0.45
TP53BP1 Q12888 5/20 0.44
MBTD1 Q05BQ5 3/20 0.44
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44
CHRM5 P08912 1/20 0.44
CHRM1 P11229 1/20 0.44
ADRA2C P18825 1/20 0.44
CHRM3 P20309 1/20 0.44
OPRK1 P41145 1/20 0.44
L3MBTL4 Q8NA19 1/20 0.44
PHF20 Q9BVI0 1/20 0.44
MORF4L1 Q9UBU8 1/20 0.44
KDM4E B2RXH2 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5873146 0.91 MEN1 (0.44) L3MBTL3L3MBTL1MAP2K2MAP2K1MEN1
SCHEMBL5872791 0.89 MAP2K1 (0.48) MAP2K2MAP2K1MEN1KMT2ATDP1
SCHEMBL5872766 0.85 MAP2K1 (0.52) MAP2K2MAP2K1MEN1KMT2ATDP1
SCHEMBL5872765 0.85 MAP2K1 (0.52) MAP2K2MAP2K1MEN1KMT2ATDP1
SCHEMBL5872799 0.85 MAP2K1 (0.49) L3MBTL1MAP2K2MAP2K1MEN1KMT2A
SCHEMBL5872821 0.85 MEN1 (0.49) MAP2K2MAP2K1MEN1KMT2ATDP1
SCHEMBL5873116 0.84 MAP2K1 (0.48) MAP2K2MAP2K1MEN1KMT2ATDP1
SCHEMBL5872784 0.84 MAP2K1 (0.50) MAP2K2MAP2K1MEN1KMT2ATDP1
SCHEMBL5872758 0.82 MAP2K1 (0.47) MAP2K2MAP2K1MEN1KMT2ATDP1
SCHEMBL5872829 0.81 MEN1 (0.47) MAP2K2MAP2K1MEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7001905-B2 Substituted diarylamines as MEK inhibitors WARNER-LAMBERT COMPANY (US) 2006-02-21 US disclosed
US-20030225076-A1 5-Amide substituted diarylamines as mex inhibitors BIWERSI CATHLIN (US) 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225076-A1 5-Amide substituted diarylamines as mex inhibitors NRAS, MAPK6, MAPK12 L3MBTL3 3446/4885L3MBTL1 2631/4885MAP2K2 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.